LUGPA 2026 BPH CME Webinar Series

Optimizing the Management of Benign Prostatic Hyperplasia:
Evidence-Based Approaches, Emerging Therapies, and Clinical Decision-Making

Visit LUGPALearn to access this CME on demand 

Faculty:

This three-part webinar series provides a practical, evidence-based framework for managing benign prostatic hyperplasia (BPH) across the full treatment spectrum. Sessions cover accurate evaluation and medical therapy for lower urinary tract symptoms, selection of minimally invasive and surgical procedures for moderate prostate enlargement, and treatment strategies for large and complex prostates, equipping clinicians with guidance on patient selection, procedural trade-offs, and individualized treatment planning. Each webinar will offer one AMA PRA Category 1 Credit™ for continuing medical education (CME).

Webinar 1: 
Beyond the Alpha-Blocker: Smarter Evaluation and Medical Therapy for BPH

This session reviews a structured approach to evaluating men with lower urinary tract symptoms (LUTS) and highlights why accurate diagnosis—not just symptom scores—is essential to appropriate BPH management. It explores guideline-based use of medical therapies, including α-blockers, 5-α-reductase inhibitors, and combination strategies, while emphasizing common gaps in real-world clinical evaluation.

Webinar 2: 
Choosing the Right Procedure:

Minimally Invasive Therapies for Moderately Enlarged Prostates

This presentation compares minimally invasive and endoscopic procedural options for prostates ≤80 cc, including prostatic urethral lift, water vapor thermal therapy, temporary implantable devices, laser vaporization, holmium laser enucleation, and transurethral resection. It focuses on patient selection, procedural trade-offs, durability, recovery, and preservation of sexual function to support shared decision-making in clinical practice.

Webinar 3: 
Treatment Strategies for Large and Very Large Prostates

This session reviews treatment approaches for large prostate glands (>80 cc), including HoLEP, robotic simple prostatectomy, prostate artery embolization, and robotic waterjet therapy. It examines clinical outcomes, procedural advantages and limitations, and comparative evidence to guide optimal intervention selection in complex BPH cases.

Accreditation Details

This activity has been planned and implemented in accordance with the accreditation requirements and
policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint
providership of PeerPoint Medical Education Institute and the Urology Alliance. PeerPoint Medical
Education Institute is accredited by the ACCME to provide continuing medical education for physicians.

PeerPoint Medical Education Institute designates the enduring format for this educational activity for a
maximum of 3.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with
the extent of their participation in the activity.
Enduring activity date: June 21, 2026 – June 21, 2029